LQB ‑118 compound inhibits migration and induces cell death in glioblastoma cells.
In conclusion, the present data demonstrated that LQB‑118 maintained its effectiveness in a 3D cell conformation, which shares more similarities with the tumor mass. LQB‑118 is a promising agent for GBM treatment as monotherapy and associated with radiotherapy or cisplatin. Its effect is associated with inhibition of GBM‑related survival signaling pathways.
PMID: 31746438 [PubMed - as supplied by publisher]
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
More News: Alternative and Complementary Therapies | Astrocytoma | Brain | Brain Cancers | Brain Tumor | Cancer & Oncology | Chemotherapy | Complementary Medicine | Neurology | Study | Temodar